AR022952A1 - ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL - Google Patents

ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL

Info

Publication number
AR022952A1
AR022952A1 ARP000101168A ARP000101168A AR022952A1 AR 022952 A1 AR022952 A1 AR 022952A1 AR P000101168 A ARP000101168 A AR P000101168A AR P000101168 A ARP000101168 A AR P000101168A AR 022952 A1 AR022952 A1 AR 022952A1
Authority
AR
Argentina
Prior art keywords
fragment
neutralizing
roedor
interleuquine
immonoglobulin
Prior art date
Application number
ARP000101168A
Other languages
English (en)
Original Assignee
Smithkline Beecham Corp
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp, Smithkline Beecham Plc filed Critical Smithkline Beecham Corp
Publication of AR022952A1 publication Critical patent/AR022952A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
ARP000101168A 1999-03-19 2000-03-16 ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL AR022952A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12529999P 1999-03-19 1999-03-19

Publications (1)

Publication Number Publication Date
AR022952A1 true AR022952A1 (es) 2002-09-04

Family

ID=22419067

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000101168A AR022952A1 (es) 1999-03-19 2000-03-16 ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL

Country Status (28)

Country Link
US (2) US6706487B1 (es)
EP (2) EP1163271B1 (es)
JP (1) JP2002542769A (es)
KR (1) KR100697120B1 (es)
CN (1) CN1246335C (es)
AR (1) AR022952A1 (es)
AT (1) ATE402191T1 (es)
AU (1) AU764622B2 (es)
BR (1) BR0008688A (es)
CA (1) CA2368965C (es)
CO (1) CO5470287A1 (es)
CY (1) CY1108387T1 (es)
CZ (1) CZ303704B6 (es)
DE (1) DE60039589D1 (es)
DK (1) DK1163271T3 (es)
ES (1) ES2308974T3 (es)
HK (1) HK1043798B (es)
HU (1) HU228931B1 (es)
IL (1) IL144995A0 (es)
MY (1) MY124219A (es)
NO (1) NO330391B1 (es)
NZ (1) NZ513699A (es)
PL (1) PL202396B1 (es)
PT (1) PT1163271E (es)
SI (1) SI1163271T1 (es)
TR (3) TR200202254T2 (es)
WO (1) WO2000056771A1 (es)
ZA (1) ZA200107639B (es)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5852266A (en) * 1993-07-14 1998-12-22 Hitachi, Ltd. Vacuum circuit breaker as well as vacuum valve and electric contact used in same
US7220717B2 (en) 1997-08-14 2007-05-22 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use
US7704944B2 (en) 1997-08-14 2010-04-27 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use for the treatment of sepsis
IL121860A0 (en) 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
CA2276216A1 (en) * 1998-06-24 1999-12-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo An artificial peptide capable of neutralizing the biological activity of interleukin-18
AR022952A1 (es) * 1999-03-19 2002-09-04 Smithkline Beecham Corp ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL
US7229619B1 (en) 2000-11-28 2007-06-12 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
ATE474854T1 (de) * 2000-01-27 2010-08-15 Medimmune Llc Rsv neutralisierende antikörper mit sehr hohen affinität
KR20110032012A (ko) * 2000-02-10 2011-03-29 아보트 러보러터리즈 사람 인터류킨-１８에 결합하는 항체 및 이를 제조하고 사용하는 방법
HU227752B1 (en) * 2000-02-21 2012-02-28 Yeda Res & Dev Use of il-18 inhibitors
AU2002224417A1 (en) * 2000-10-18 2002-04-29 Immunex Corporation Methods for treating il-18 mediated disorders
US7179900B2 (en) 2000-11-28 2007-02-20 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US20040018195A1 (en) * 2002-03-26 2004-01-29 Griswold Don Edgar Diabetes-related immunoglobulin derived proteins, compositions, methods and uses
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
AU2002343870A1 (en) * 2002-11-07 2004-06-07 Kumamoto Technology And Industry Foundation Transgenic mammal carrying ganp and utilization thereof
CA2523912A1 (en) 2003-04-30 2004-11-11 Japan Science And Technology Agency Human antihuman interleukin-18 antibody, fragment thereof and method of using the same
US7968684B2 (en) * 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
US20050100965A1 (en) * 2003-11-12 2005-05-12 Tariq Ghayur IL-18 binding proteins
AU2011224023C1 (en) * 2003-11-12 2013-08-29 Abbvie Inc. IL-18 binding proteins
US7141382B1 (en) 2004-10-12 2006-11-28 Parikh Chirag R Methods for detection of IL-18 as an early marker for diagnosis of acute renal failure and predictor of mortality
NZ567124A (en) 2005-10-21 2011-08-26 Novartis Ag Human antibodies against Interleukin-13 and therapeutic uses to treat asthma
GB0610438D0 (en) * 2006-05-25 2006-07-05 Glaxo Group Ltd Immunoglobulins
SG172625A1 (en) * 2006-05-25 2011-07-28 Glaxo Group Ltd Modified humanised anti-interleukin-18 antibodies
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
WO2009048539A2 (en) 2007-10-05 2009-04-16 Genentech, Inc. Monoclonal antibody
AU2008312802A1 (en) * 2007-10-19 2009-04-23 Immunas Pharma, Inc. Antibody capable of specifically binding to abeta oligomer, and use thereof
US20100291071A1 (en) * 2008-08-01 2010-11-18 Immunas Pharma, Inc. Antibody Specific Binding to A-Beta Oligomer and the Use
AU2009211635B2 (en) 2008-02-08 2014-06-26 Immunas Pharma, Inc. Antibody capable of binding specifically to Abeta-oligomer, and use thereof
EP2281004A4 (en) * 2008-04-14 2012-02-15 Proscan Rx Pharma Inc PROSTATE-SPECIFIC MEMBRANANT ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS
US9085614B2 (en) 2008-08-01 2015-07-21 Immunas Pharma, Inc. Antibodies that specifically bind to Aβ oligomers and uses thereof
US20110150871A1 (en) * 2008-08-18 2011-06-23 Glaxo Group Limited Treatment of an autoimmune disease using il-18 antagonists
WO2010040736A2 (en) * 2008-10-07 2010-04-15 Ablynx Nv Amino acid sequences directed against il18 and/or the il-18 receptor and polypeptides comprising the same for the treatment of diseases and/or disorders associated with il-18 mediated signaling
US8168165B2 (en) * 2008-12-23 2012-05-01 Abbott Laboratories Alkylated interleukin-18 compositions
DK2419447T3 (en) 2009-04-17 2017-09-25 Immunas Pharma Inc ANTIBODIES THAT SPECIFICALLY BIND TO A BETA OLIGOMER AND USE THEREOF
KR20120034068A (ko) * 2009-06-30 2012-04-09 가부시키가이샤 고센 라켓용 스트링과 그 제조 방법 및 이것을 장설한 라켓
ES2614949T3 (es) 2009-08-06 2017-06-02 Immunas Pharma, Inc. Anticuerpos que se unen específicamente a oligómeros beta A y uso de los mismos
ES2624835T3 (es) 2009-08-06 2017-07-17 Immunas Pharma, Inc. Anticuerpos que se unen específicamente a los oligómeros A beta y uso de los mismos
CN105131112A (zh) 2009-08-29 2015-12-09 Abbvie公司 治疗用dll4结合蛋白
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
JP2013518863A (ja) * 2010-02-09 2013-05-23 グラクソ グループ リミテッド 代謝障害の治療
WO2011106697A1 (en) 2010-02-25 2011-09-01 Schepens Eye Research Institute Therapeutic compositions for the treatment of dry eye disease
MY160628A (en) 2010-03-02 2017-03-15 Abbvie Inc Therapeutic DLL4 Binding Proteins
WO2011150086A2 (en) * 2010-05-25 2011-12-01 The Regents Of The University Of Colorado, A Body Corporate Diagnosis and treatment of autoimmune disease
RU2607368C2 (ru) 2010-07-30 2017-01-10 Ац Иммуне С.А. Безопасные и функциональные гуманизированные антитела
EP2655416A1 (en) 2010-12-20 2013-10-30 Medimmune Limited Anti-il-18 antibodies and their uses
JOP20200308A1 (ar) 2012-09-07 2017-06-16 Novartis Ag جزيئات إرتباط il-18
US10570199B2 (en) 2012-11-21 2020-02-25 Km Biologics Co., Ltd. Human antibody against IL-18
MY194040A (en) * 2015-03-05 2022-11-09 Ab2 Bio Sa Il-18 binding protein (il-18bp) and antibodies in inflammatory diseases
JP2023530489A (ja) * 2020-06-18 2023-07-18 ネクストキュア インコーポレイテッド Ｆｌｒｔ３媒介性シグナル伝達を調節するための組成物及び方法
JPWO2023286694A1 (es) 2021-07-13 2023-01-19

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) * 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
PT528767E (pt) * 1991-08-21 2000-06-30 Novartis Ag Derivados de anticorpos
GB9125979D0 (en) * 1991-12-06 1992-02-05 Wellcome Found Antibody
TW581771B (en) 1994-11-15 2004-04-01 Hayashibara Biochem Lab Recombinant production of a polypeptide for inducing interferon-gamma production, and monoclonal antibody against the polypeptide
IL121860A0 (en) 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
FR2767697B1 (fr) 1997-09-01 2000-05-05 Boots Co Plc Composition dermatologique permettant d'eviter l'apparition de symptomes d'hypersensibilite et d'intolerance cutanee
CA2276216A1 (en) * 1998-06-24 1999-12-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo An artificial peptide capable of neutralizing the biological activity of interleukin-18
AR022952A1 (es) * 1999-03-19 2002-09-04 Smithkline Beecham Corp ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL

Also Published As

Publication number Publication date
PL202396B1 (pl) 2009-06-30
TR200102733T2 (tr) 2002-04-22
CA2368965C (en) 2010-05-18
PL350460A1 (en) 2002-12-16
HUP0200502A3 (en) 2003-12-29
ZA200107639B (en) 2002-09-17
ES2308974T3 (es) 2008-12-16
NZ513699A (en) 2004-02-27
CZ303704B6 (cs) 2013-03-27
SI1163271T1 (sl) 2008-10-31
KR20020008130A (ko) 2002-01-29
DK1163271T3 (da) 2008-11-10
BR0008688A (pt) 2002-01-08
PT1163271E (pt) 2008-09-16
CA2368965A1 (en) 2000-09-28
CO5470287A1 (es) 2004-12-30
TR200202254T2 (tr) 2002-12-23
CZ20013362A3 (cs) 2002-03-13
NO330391B1 (no) 2011-04-04
HK1043798A1 (en) 2002-09-27
HK1043798B (zh) 2009-04-09
IL144995A0 (en) 2002-06-30
KR100697120B1 (ko) 2007-03-20
AU3901600A (en) 2000-10-09
US20040141964A1 (en) 2004-07-22
CY1108387T1 (el) 2014-02-12
WO2000056771A1 (en) 2000-09-28
EP1163271A1 (en) 2001-12-19
ATE402191T1 (de) 2008-08-15
AU764622B2 (en) 2003-08-28
DE60039589D1 (de) 2008-09-04
US6706487B1 (en) 2004-03-16
HU228931B1 (en) 2013-06-28
HUP0200502A2 (en) 2002-06-29
EP1163271B1 (en) 2008-07-23
JP2002542769A (ja) 2002-12-17
EP1163271A4 (en) 2003-04-09
TR200202253T2 (tr) 2002-12-23
CN1246335C (zh) 2006-03-22
CN1352650A (zh) 2002-06-05
NO20014524L (no) 2001-11-14
EP1961768A1 (en) 2008-08-27
NO20014524D0 (no) 2001-09-18
MY124219A (en) 2006-06-30

Similar Documents

Publication Publication Date Title
AR022952A1 (es) ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL
IL172871A (en) Isolated human antibody or antigen-binding section, training linker, single-chain antibody molecule, polypeptide containing them and their use
NZ604090A (en) Human anti-b7rp1 neutralizing antibodies
CY2012019I2 (el) Ανθρωπινα μονοκλωνα αντισωματα εναντια στο cd20
HRP20151252T4 (hr) Modificirani fab ulomci protutijela
PE20090046A1 (es) Anticuerpo recombinante humanizado anti-interleuquina 10
IL202348A (en) A light chain variable polypeptide of 2her antibody
NZ599196A (en) Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
RS52860B (en) ANTI-ILT7 ANTITELO
HRP20020693B1 (en) HUMANIZED ANTIBODIES THAT SEQUESTER AMYLOID Abeta PEPTIDE
IL173323A0 (en) Antibodies directed to parathyroid hormone (pth) and uses thereof
IL165193A0 (en) Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
PE20100251A1 (es) Anticuerpos anti-5t4 humanizados y conjugados anticuerpo anti-5t4/calicheamicina
ECSP066432A (es) Moléculas de enlace terapéuticas
CR20140001A (es) Anticuerpos para el receptor de factor de crecimiento y similares a la insulina
DE60222658D1 (de) Monoklonaler anti-cd-40-antikörper
CO5160384A1 (es) Anticuerpo humanizado especifico para 4-1bb humano y composicion farmaceutica que comprende el mismo
DK1718677T3 (da) Monovalente antistoffragmenter egnede som terapeutiske midler
WO2006039258A3 (en) Human antibodies against parathyroid hormone
PL375144A1 (en) Humanized antibodies against human 4-1bb
DK1636268T3 (da) Humaniserede antistoffer, som genkender beta-amyloidpeptid
EE200300179A (et) Humaniseeritud LT-ß-R-i vastased antikehad
IN2009KN02655A (es)
ATE417067T1 (de) Rs7 antikörper
EP1245886A3 (de) Mehrlagiger Schlauch aus profiliertem Bandmaterial

Legal Events

Date Code Title Description
FG Grant, registration